1. Introduction {#s0005}
===============

Diabetes mellitus (-a group of the metabolic disorders), is characterized by hyperglycemia, and is resulting from the defects in the secretion and action of the insulin \[-a protein (hormone)\] or both produced by the pancreas ([@b0080]). The global burden of the disease diabetes in the year 2017 only was approximately 425 million, which have been estimated to increase up to 629 million by 2045 ([@b0115]). There have been several insulin as well as oral hypoglycemic agents which are under trade for the management of diabetes ([@b0100]); however, its use lead to various side effects ([@b0130]). Therefore, identification of natural products having antidiabetic activity with least side effects become immense importance nowadays ([@b0100]).

Traditional knowledge of ethnic communities is the most reliable source to know the healing properties of plant species for various ailments ([@b0210], [@b0215]). Recently bioinformatics tools like 'Prediction of Activity Spectra for Substances' (PASS) are much helpful to find the possible medicinal uses of certain bioactive compounds of ethnobotanical significance ([@b0025]). The information collected from the ethnic communities and the tools of bioinformatics are used to identify and select plants of medicinal importance for further scientific validation. The 'Irula' (-one of the oldest tribal communities of India, migrated from Africa) belongs to the Negrito race, has wide knowledge in using plants for their health care ([@b0225], [@b0210], [@b0215]). *Solena amplexicaulis* (Lam.) Gandhi (family Cucurbitaceae) is the rare sighted climber, inhabiting in the dry deciduous forests of southern India, is being used by Irula tribes of Walayar valley of the Western Ghats of Tamil Nadu, India for the management of diabetes since long back ([@b0125]).

Diabetes is affiliated with the increased ROS (free radicals) formation of tilting the balance of oxidant/antioxidant defense system of the human body ([@b0095]); as a result, there is alteration in enzymatic systems, impaired Glutathione metabolism, lipid peroxidation and lower level of Vitamin C. In the diabetes, catalane, lipids, proteins, Glutathione, DNA damage, and superoxide dismutase are various biomarkers of oxidative stress ([@b0010]). We have previously been reported that *S. amplexicaulis* is rich in polyphenols with strong antioxidant activity ([@b0070]), and the bioinformatics software 'PASS' also predicted that the Forskolin (-an isolated compound from *S. amplexicaulis*) have antidiabetic property.; this has prompted us for the *in vivo* evaluation of antidiabetic and antihyperlipidemic properties of methanolic extract of *S. amplexicaulis* and Forskolin (-the major components of methanolic extract of *S. amplexicaulis*) using streptozotocin (STZ) induced diabetic rats.

2. Materials and methods {#s0010}
========================

2.1. Preparation of test samples {#s0015}
--------------------------------

The leaves of *S. amplexicaulis* were collected from Madukkarai (Coimbatore, India), and the taxonomic authentication was confirmed by comparing the reference specimen (Vide No: CPS 313) housed at Botanical Survey of India, Coimbatore. The powdered leaves (1000 g) were exhaustively extracted with methanol after de-waxing with petroleum ether using soxhlet apparatus, concentrated up to dryness using rotary evaporator, and then stored at −20 °C temperature until used in the experiments. The methanolic crude extract (MeOHSa) yield was 18.6% w/w (dry weight basis). The spectral data and also our report published earlier confirmed that the chemical structure of the isolated compound as Forskolin \[((3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo\[f\]chromen-5-yl acetate)\] ([@b0065]). The isolation of Forskolin was made using wet packing method of silica gel (60--120 mesh) using column chromatography ([@b0150]).

2.2. Experimental animals {#s0020}
-------------------------

The animal studies conducted on male wistar albino rats (150--250 g) were approved (No: 659/02/a/CPCSEA) by Institutional Animal Ethical Committee (IAEC). In order to evaluate the behavioral and toxicological effects, the acute toxicity was evaluated following Organization for Economic Cooperation and Development (OECD) guideline 423 (2001). The rats were divided into eleven groups (n = 6) each (the first group served as control, the groups 2--8 were orally treated with MeOHSa at the doses of 50, 150, 300, 500, 1000, 2000 and 3000 mg/kg body weight (b.w.) respectively, and the groups 9--11 received oral doses of 10, 50 and 100 mg/kg b.w. of Forskolin respectively). The observations were made for mortality and clinical signs up to 14 days.

2.3. Oral glucose tolerance test (OGTT) {#s0025}
---------------------------------------

A total number of 24 rats (assigned randomly into four equal groups) were fasted for 16 h, and then were orally treated \[Group 1: 1 ml of distilled water (control), Group 2: 600 mg/kg b.w. of MeOHSa, Group 3: 10 mg/kg b.w. Forskolin, Group 4: 600 μg/kg b.w. of standard Glibenclamide (Sigma- Aldrich Chemicals, India)\] followed by 5 ml/kg of 50% (w/v) glucose solution after 1 h, and then the blood glucose levels were estimated (using Accu-chek, Roche Diagnostics, USA) after 60, 120 and 240 min.

2.4. Antidiabetic effect of MeOHSa and Forskolin in type 1 diabetes induced rats {#s0030}
--------------------------------------------------------------------------------

### 2.4.1. Induction of IDDM {#s0035}

The insulin dependent diabetes mellitus was induced in overnight fasted wistar albino rats by the single dose of intraperitoneal injection of Streptozotocin (Sigma- Aldrich Chemicals, India) (50 mg/kg b.w.) (0.01 M, pH 4.5). After Streptozotocin administration, in order to stave off the hypoglycaemic shock, the rats were given 5% (w/v) glucose orally. The massive glycosuria and hyperglycemia were noted in the rats within two days after administration of Streptozotocin. The rats with blood glucose levels above 250 mg/dl were considered diabetic, and were selected for the further study.

### 2.4.2. Experimental regime {#s0040}

The diabetic rats were divided into five groups (n = 6), and were fed orally by gastric intubation once daily for 30 days in the following manner: Group 1 (Normoglycemic, control group), Group 2 (Streptozotocin-induced diabetic rats), Group 3 (MeOHSa, 600 mg/kg b.w.), Group 4 (Forskolin, 10 mg/kg b.w.), Group 5 (Glibenclamide, 600 μg/kg b.w.). The third day of induction was designated as day 1 for extract administration in diabetic rats. The fasting blood glucose levels were monitored at the interval of 10 days of administration using glucometer elite (glucose oxidase method). All the animals were sacrificed at 30th days, the blood samples were collected. The fresh serum was collected, and stored at −20 °C until further analysis of blood. The pancreas, liver and kidney were carefully excised, and fixed in 10% Formolsaline. The body weight of animals was recorded.

### 2.4.3. Biochemical analysis {#s0045}

The Serum Glutamate Oxaloacetate Transaminase (SGOT), Serum Glutamate Pyruvate Transaminase (SGPT) and the levels of High and Low Density Lipoproteins (HDL and LDL), Total Cholesterol (TC) and Triglycerides (TG) in serum were assessed in an autoanalyzer (MISPA EXCEL, India). The fresh blood samples were drawn in heparinized tube, and their total haemoglobin content was estimated ([@b0140]). The hepatic glycogen level estimated following method of [@b0180]. The activities of Lipid Peroxidation ([@b0105]), Catalase (CAT) ([@b0195]), Superoxide Dismutase (SOD) ([@b0085]), Glutathione-S-Transferase (GST) ([@b0035]), Glutathione Peroxidase (GPx) ([@b0175]), Reduced Glutathione ([@b0090]) and Vitamin C ([@b0120]) were determined in hepatic and renal tissues.

### 2.4.4. Histopathological studies {#s0050}

The whole pancreas from each animal were fixed in 10% Formolsaline, and were cut into ultra-thin sections, stained and mounted, and the histological architecture at 10× and 40× magnification in Axiostar plus microscope (Carl Zeiss, Germany).

2.5. Statistical analysis {#s0055}
-------------------------

The results were presented as mean ± S.E.M (n = 6), one-way analysis of variance (ANOVA) were performed followed by Tukey's multiple comparison test, with the help of Graph Pad Prism version 4.0 (Graph Pad software, San Diego, California, USA). *P* \< 0.001 was considered as significant.

3. Results and discussion {#s0060}
=========================

An oral load of 2.5 gm glucose resulted in nearly two fold raise of blood glucose level in 60 min which progressively decreased towards normalcy over the period of time; however, pretreatment with MeOHSa) and Forskolin or Glibenclamide significantly lead to the blood glucose levels towards normalcy. Interestingly, the efficacy of Forskolin was lower as compared to Glibenclamide ([Fig. 1](#f0005){ref-type="fig"}). The hypoglycemic effect of Forskolin might be due to the enhanced glucose-mediated stimulus to release insulin; this effect produced by the elevation of CAMP which activates main signaling pathways in beta cells viz., Protein Kinase (PKA) pathway and guanine nucleotide pathway regulated by CAMP ([@b0155]). Further, the administration of the MeOHSa and Forskolin significantly increases the body weight ([Table 1](#t0005){ref-type="table"}) and decreases the blood glucose levels ([Table 2](#t0010){ref-type="table"}). The significant climb in the level of the total haemoglobin content, the reversal of the transaminase enzyme (SGOT and SGPT) activities towards their respective normal levels, the significant restoration of the lipid profile to the normalcy, increase in the glycogen content of the liver after the administration of Forskolin ([Table 3](#t0015){ref-type="table"}) further strengthen its antidiabetogenic effect which might be due to ability of antidiabetic compound to reduce hyperglycemia ([@b0190]) through insulin release stimulatory effect ([@b0220]) and the sensitization of insulin receptors and reactivation of glycogen synthase system involved in the glycogen synthesis ([@b0050], [@b0170]).Fig. 1Effect of MeOHSa and Forskolin on OGT. Values are mean ± SEM (n = 6). ^a^*P* \< 0.001, significantly different from the respective control group.Table 1Effect of MeOHSa and Forskolin on body weight in diabetic rats.Treatment groupBody weight (g)Initial ([\*](#tblfn1){ref-type="table-fn"}Day 1)Final (Day 30)Control233.3 ± 10.5271.7 ± 11.8Diabetic control183.3 ± 9.8115.0 ± 11.2[a](#tblfn2){ref-type="table-fn"} (−37.3%)Diabetic + MeOHSa (600 mg/kg b.w.)176.7 ± 12.0195.0 ± 7.2[a](#tblfn2){ref-type="table-fn"}^,^[b](#tblfn3){ref-type="table-fn"} (+10.4%)Diabetic + Forskolin (10 mg/kg b.w.)173.3 ± 13.3220.0 ± 9.1[b](#tblfn3){ref-type="table-fn"} (+26.9%)Diabetic + Glibenclamide (600 µg/kg b.w.)176.7 ± 10.5228.3 ± 12.1[b](#tblfn3){ref-type="table-fn"} (+29.2%)[^1][^2][^3][^4]Table 2Effect of MeOHSa and Forskolin on blood glucose level in STZ induced diabetic rats.Treatment groupBlood glucose level (mg/dL)0 day1st day[\*](#tblfn4){ref-type="table-fn"}10th day20th day30th dayControl83.3 ± 1.482.0 ± 2.185.0 ± 2.186.5 ± 1.586.3 ± 2.3Diabetic control78.5 ± 4.2420.5 ± 1.8432.8 ± 3.0[a](#tblfn5){ref-type="table-fn"} (+2.9%)450.0 ± 5.3[a](#tblfn5){ref-type="table-fn"} (+7.0%)467.0 ± 1.0[a](#tblfn5){ref-type="table-fn"} (+11.1%)Diabetic + MeOHSa (600 mg/kg b.w.)86.0 ± 3.0415.0 ± 0.7356.0 ± 2.4[a](#tblfn5){ref-type="table-fn"} (−14.2%)320.0 ± 1.5[a](#tblfn5){ref-type="table-fn"}^,^[e](#tblfn8){ref-type="table-fn"} (−23.0%)235.3 ± 1.4[b](#tblfn6){ref-type="table-fn"}^,^[d](#tblfn7){ref-type="table-fn"} (−43.3%)Diabetic + Forskolin (10 mg/kg b.w.)83.0 ± 2.0412.8 ± 2.1334.8 ± 1.8[a](#tblfn5){ref-type="table-fn"}^,^[f](#tblfn9){ref-type="table-fn"} (−18.9%)262.0 ± 1.5[b](#tblfn6){ref-type="table-fn"}^,^[d](#tblfn7){ref-type="table-fn"} (−36.5%)156.5 ± 1.7[d](#tblfn7){ref-type="table-fn"} (−62.1%)Diabetic + Glibenclamide (600 µg/kg)79.0 ± 2.4418.5 ± 0.6307.3 ± 3.8[a](#tblfn5){ref-type="table-fn"}^,^[e](#tblfn8){ref-type="table-fn"} (−26.6%)219.8 ± 1.0[b](#tblfn6){ref-type="table-fn"}^,^[d](#tblfn7){ref-type="table-fn"} (−47.5%)118.3 ± 2.9[d](#tblfn7){ref-type="table-fn"} (−71.7%)[^5][^6][^7][^8][^9][^10][^11][^12]Table 3Effect of MeOHSa and Forskolin on various biochemical markers in STZ induced diabetic rats.Parameter[\*](#tblfn10){ref-type="table-fn"}Treatment groupControlDiabetic controlDiabetic + MeOHSa (600 mg/kg b.w.)Diabetic + Forskolin (10 mg/kg b.w.)Diabetic + Glibenclamide (600 µg/kg b.w.)Haemoglobin (%)14.5 ± 0.46.9 ± 0.2[a](#tblfn11){ref-type="table-fn"}12.5 ± 0.5[b](#tblfn12){ref-type="table-fn"}^,^[d](#tblfn13){ref-type="table-fn"}13.3 ± 0.4[d](#tblfn13){ref-type="table-fn"}13.9 ± 0.3[d](#tblfn13){ref-type="table-fn"}SGOT (IU/L)41.6 ± 2.8112.3 ± 3.6[a](#tblfn11){ref-type="table-fn"}49.4 ± 1.5[d](#tblfn13){ref-type="table-fn"}44.2 ± 1.7[d](#tblfn13){ref-type="table-fn"}42.6 ± 4.7[d](#tblfn13){ref-type="table-fn"}SGPT (IU/L)28.2 ± 6.4102.6 ± 1.4[a](#tblfn11){ref-type="table-fn"}57.1 ± 5.2[b](#tblfn12){ref-type="table-fn"}[d](#tblfn13){ref-type="table-fn"}30.6 ± 2.5[d](#tblfn13){ref-type="table-fn"}32.9 ± 7.5[d](#tblfn13){ref-type="table-fn"}HDL (mg/dL)52.8 ± 8.711.4 ± 2.0[a](#tblfn11){ref-type="table-fn"}43.5 ± 7.6[e](#tblfn14){ref-type="table-fn"}51.8 ± 5.0[d](#tblfn13){ref-type="table-fn"}49.1 ± 0.1[d](#tblfn13){ref-type="table-fn"}LDL (mg/dL)82.8 ± 5.6231.9 ± 2.5[a](#tblfn11){ref-type="table-fn"}95.2 ± 4.3[d](#tblfn13){ref-type="table-fn"}84.5 ± 1.3[d](#tblfn13){ref-type="table-fn"}88.2 ± 8.7[d](#tblfn13){ref-type="table-fn"}TC (mg/dL)156.3 ± 4.6280.4 ± 1.4[a](#tblfn11){ref-type="table-fn"}161.6 ± 5.2[d](#tblfn13){ref-type="table-fn"}157.8 ± 2.7[d](#tblfn13){ref-type="table-fn"}159.3 ± 2.5[d](#tblfn13){ref-type="table-fn"}TG (mg/dL)103.3 ± 1.1185.7 ± 1.6[a](#tblfn11){ref-type="table-fn"}114.7 ± 8.1[d](#tblfn13){ref-type="table-fn"}107.4 ± 8.1[d](#tblfn13){ref-type="table-fn"}109.8 ± 5.3[d](#tblfn13){ref-type="table-fn"}Glycogen (mg/g liver tissue)19.0 ± 1.95.2 ± 1.4[a](#tblfn11){ref-type="table-fn"}14.4 ± 0.5[f](#tblfn15){ref-type="table-fn"}18.8 ± 3.7[d](#tblfn13){ref-type="table-fn"}18.6 ± 0.7[d](#tblfn13){ref-type="table-fn"}[^13][^14][^15][^16][^17][^18][^19][^20]

Diabetes is associated with the increased in the formation of free radicals, tilting the balance of oxidant/antioxidant defense system ([@b0095]). The administration of the MeOHSa and Forskolin significantly (*P* \< 0.05) improved the activities of enzymic and non-enzymic antioxidants in the diabetic rats ([Table 4](#t0020){ref-type="table"}). In addition, the administration of Forskolin markedly ameliorated islet damage comparable with Glibenclamide ([Fig. 2](#f0010){ref-type="fig"}).Table 4Effect of MeOHSa and forskolin on antioxidant markers in STZ induced diabetic rats.Parameter[\*](#tblfn16){ref-type="table-fn"}ControlDiabetic controlDiabetic + MeOHSa(600 mg/kg b.w.)Diabetic + forskolin (10 mg/kg b.w.)Diabetic + glibenclamide (600 µg/kg b.w.)*LPO (µ moles of malondialdehyde (MDA) formed/mg protein)*Liver8.4 ± 0.917.8 ± 0.7[a](#tblfn17){ref-type="table-fn"}10.3 ± 0.3[d](#tblfn20){ref-type="table-fn"}9.0 ± 0.2[d](#tblfn20){ref-type="table-fn"}8.9 ± 0.8[d](#tblfn20){ref-type="table-fn"}Kidney7.1 ± 0.416.2 ± 1.4[a](#tblfn17){ref-type="table-fn"}8.4 ± 1.2[e](#tblfn21){ref-type="table-fn"}7.9 ± 0.5[d](#tblfn20){ref-type="table-fn"}7.9 ± 2.1[d](#tblfn20){ref-type="table-fn"}*SOD (units/mg protein)*Liver38.4 ± 0.917.6 ± 1.3[a](#tblfn17){ref-type="table-fn"}28.5 ± 3.2^bd^37.7 ± 0.7[d](#tblfn20){ref-type="table-fn"}35.8 ± 0.6[d](#tblfn20){ref-type="table-fn"}Kidney38.8 ± 1.915.3 ± 3.0[a](#tblfn17){ref-type="table-fn"}29.1 ± 1.9 ^cd^35.5 ± 2.0[d](#tblfn20){ref-type="table-fn"}32.5 ± 1.1[d](#tblfn20){ref-type="table-fn"}  *CAT (µ moles of hydrogen peroxide consumed/min/mg protein)*Liver62.8 ± 4.121.2 ± 0.1[a](#tblfn17){ref-type="table-fn"}51.2 ± 0.2[b](#tblfn18){ref-type="table-fn"}^,^[d](#tblfn20){ref-type="table-fn"}59.5 ± 0.3[d](#tblfn20){ref-type="table-fn"}60.4 ± 0.4[d](#tblfn20){ref-type="table-fn"}Kidney53.0 ± 3.618.5 ± 0.1[a](#tblfn17){ref-type="table-fn"}45.0 ± 0.2[c](#tblfn19){ref-type="table-fn"}^,^[d](#tblfn20){ref-type="table-fn"}52.0 ± 2.2[d](#tblfn20){ref-type="table-fn"}51.4 ± 0.4[d](#tblfn20){ref-type="table-fn"}  *GPx (µ moles of reduced glutathione utilized/min/mg protein)*Liver3.1 ± 0.21.1 ± 0.1[a](#tblfn17){ref-type="table-fn"}1.9 ± 0.1[b](#tblfn18){ref-type="table-fn"}^,^[f](#tblfn22){ref-type="table-fn"}3.0 ± 0.3[d](#tblfn20){ref-type="table-fn"}2.8 ± 0.2[d](#tblfn20){ref-type="table-fn"}Kidney2.2 ± 0.10.9 ± 0.1[a](#tblfn17){ref-type="table-fn"}1.7 ± 0.1[c](#tblfn19){ref-type="table-fn"}^,^[d](#tblfn20){ref-type="table-fn"}2.1 ± 0.1[d](#tblfn20){ref-type="table-fn"}2.0 ± 0.1[d](#tblfn20){ref-type="table-fn"}  *GST (units/mg protein)*Liver6.3 ± 0.22.1 ± 0.2[a](#tblfn17){ref-type="table-fn"}5.8 ± 0.1[c](#tblfn19){ref-type="table-fn"}^,^[d](#tblfn20){ref-type="table-fn"}6.2 ± 0.1[d](#tblfn20){ref-type="table-fn"}6.0 ± 0.2[d](#tblfn20){ref-type="table-fn"}Kidney5.2 ± 0.21.8 ± 0.1[a](#tblfn17){ref-type="table-fn"}3.9 ± 0.1[b](#tblfn18){ref-type="table-fn"}^,^[d](#tblfn20){ref-type="table-fn"}4.9 ± 0.1[d](#tblfn20){ref-type="table-fn"}4.8 ± 0.4[d](#tblfn20){ref-type="table-fn"}  *Vitamin C (µ moles/mg protein)*Liver13.4 ± 0.63.9 ± 0.6[a](#tblfn17){ref-type="table-fn"}9.4 ± 0.3[c](#tblfn19){ref-type="table-fn"}^,^[d](#tblfn20){ref-type="table-fn"}10.3 ± 0.3[d](#tblfn20){ref-type="table-fn"}11.5 ± 1.5[d](#tblfn20){ref-type="table-fn"}Kidney7.3 ± 0.64.5 ± 0.2[a](#tblfn17){ref-type="table-fn"}6.5 ± 0.2[e](#tblfn21){ref-type="table-fn"}7.0 ± 0.1[d](#tblfn20){ref-type="table-fn"}6.9 ± 0.2[d](#tblfn20){ref-type="table-fn"}  *GSH (µ moles/mg protein)*Liver40.8 ± 1.020.6 ± 2.5[a](#tblfn17){ref-type="table-fn"}34.7 ± 1.0[d](#tblfn20){ref-type="table-fn"}38.7 ± 0.5[d](#tblfn20){ref-type="table-fn"}36.8 ± 1.6[d](#tblfn20){ref-type="table-fn"}Kidney33.7 ± 3.712.9 ± 2.7[a](#tblfn17){ref-type="table-fn"}24.0 ± 1.0[c](#tblfn19){ref-type="table-fn"}^,^[e](#tblfn21){ref-type="table-fn"}31.9 ± 0.8[d](#tblfn20){ref-type="table-fn"}28.5 ± 0.7[d](#tblfn20){ref-type="table-fn"}[^21][^22][^23][^24][^25][^26][^27][^28]Fig. 2Photomicrograph showing (a) pancreatic islet of normal untreated control group, (b) STZ-induced diabetic group, (c) diabetic + MeOHSa (600 mg/kg b.w.) treated group, (d) diabetic + Forskolin (10 mg/kg b.w.) treated group and (e) diabetic + Glibenclamide (600 µg/kg b.w.) treated group.

There are several cucurbits are well known for their antidiabetic properties viz. *Bryonia alba* L. ([@b0060]), *Citrullus colocynthis* Schrad. ([@b0110], [@b0005]), *Coccina indica* Wight & Am. ([@b0045], [@b0075]), *Cucurbita ficifolia* Bouché ([@b0160], [@b0165]), *Momordica charantia* L. ([@b0020], [@b0040], [@b0015], [@b0205], [@b0185], [@b0145], [@b0200], [@b0055]), *Momordica cymbalaria* ([@b0135]). *S. amplexicaulis* is known to be rich in polyphenols with strong antioxidant activity ([@b0070]). Moreover, Forskolin isolated from *Coleus forskohlii* (family Lamiaceae) have previously been reported as the active antidiabetic agent ([@b0155]). As such, it is assumed that apart from its strong antioxidant potential, Forskolin might stimulate the insulin secretion from β-cells by the mechanism similar to oral hypoglycemic drugs.
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[^1]: Values are mean ± SEM (n = 6). Percent increase or decrease in body weights are given in the parenthesis.

[^2]: Day 3 of induction of diabetes.

[^3]: P \< 0.001, significantly different from the control group of day 30.

[^4]: P \< 0.001, significantly different from the diabetic control group of day 30.

[^5]: Values are mean ± SEM (n = 6). The values given in the parenthesis indicates percentage of increase or decrease in glucose concentration over 1st day.

[^6]: ^c^P \< 0.05, significantly different from the control group of the respective day.

[^7]: Day 3 of induction of diabetes.

[^8]: P \< 0.001, significantly different from the control group of the respective day.

[^9]: P \< 0.01, significantly different from the control group of the respective day.

[^10]: P \< 0.001, significantly different from the diabetic control group of the respective day.

[^11]: P \< 0.01, significantly different from the diabetic control group of the respective day.

[^12]: P \< 0.05, significantly different from the diabetic control group of the respective day.

[^13]: Values are mean ± SEM (n = 6).

[^14]: ^c^P \< 0.05, significantly different from the control group.

[^15]: SGOT - serum glutamate oxaloacetate transaminase; SGPT - serum glutamate pyruvate transaminase; HDL - high-density lipoproteins; LDL - low density lipoproteins; TC - total cholesterol; TG - triglycerides.

[^16]: P \< 0.001, significantly different from the control group.

[^17]: P \< 0.01, significantly different from the control group.

[^18]: P \< 0.001, significantly different from the diabetic control group.

[^19]: P \< 0.01, significantly different from the diabetic control group.

[^20]: P \< 0.05, significantly different from the diabetic control group.

[^21]: Values are mean ± SEM (n = 6).

[^22]: LPO - lipid peroxides; SOD - superoxide dismutase; CAT - catalase; GPx - glutathione peroxidase; GST - glutathione-s-transferase; GSH - reduced glutathione.

[^23]: P \< 0.001, significantly different from the control group.

[^24]: P \< 0.01, significantly different from the control group.

[^25]: P \< 0.05, significantly different from the control group.

[^26]: P \< 0.001, significantly different from the diabetic control group.

[^27]: P \< 0.01, significantly different from the diabetic control group.

[^28]: P \< 0.05, significantly different from the diabetic control group.
